Navigation Links
VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Date:9/15/2008

Topline Data from Phase 2 CEA and ACS Clinical Trials to be Released

Concurrent with AHA Presentation

SAN FRANCISCO, Sept. 15 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that two abstracts on the company's Phase 2 trials of VIA-2291 in patients with acute coronary syndrome (ACS) and in patients undergoing carotid endarterectomy (CEA) surgery, have been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2008, taking place November 8-12 in New Orleans, LA.

Given AHA's embargo policy, the company will announce the proof of concept data from its CEA and ACS trials concurrent with the AHA sessions.

The presentation details are as follows:

Date/Time: Sunday, November 9, 2008: 5:45 p.m. CDT

Location: Ernest N. Morial Convention Center, Room 275-277

Session: Cardiovascular Seminar: Translational Trials and Strategies:

First in Man

Title: Three Months of Treatment with 5- Lipoxygenase Inhibitor VIA-2291

in Patients with Recent Acute Coronary Syndrome

Presented by: Jean-Claude Tardif, M.D., Professor and Director, Montreal

Heart Institute, Montreal, Canada

Date/Time: Sunday, November 9, 2008: 6:00 p.m. CDT

Location: Ernest N. Morial Convention Center, Room 275-277

Session: Cardiovascular Seminar: Translational Trials and Strategies:

First in Man

Title: Three Months of Treatment with 5-Lipoxygenase Inhibitor VIA- 2291

in Patients Scheduled for Elective Carotid Endarterectomy Surgery

Presented b
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014  RESMED INC. (NYSE: ... second quarter of fiscal year 2015 results on Thursday, January ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:12/19/2014)... separating membrane market has witnessed robust development with the ... as a later starter. In 2012, the size of ... billion, with the proportion worldwide soaring to 16.3%. It is ... will continue its growth rate by around 20% in the ... to roughly RMB25 billion. An integrated membrane industrial ...
(Date:12/17/2014)... N.Y. , Dec. 17, 2014  Northstar ... The Depository Trust Company (DTC) has made their ... Deposit Chill on the Company,s stock effective December ... Northstar,s common stock for depository and book entry ... the Company is now once again fully "DTC ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3
(Date:12/19/2014)... TX (PRWEB) December 19, 2014 ... a shifting, capital equipment market that is saturated ... impressive safety and efficacy as well as non-invasive ... they were first introduced to the healthcare market. ... the development of MRI safe technologies have greatly ...
(Date:12/19/2014)... From November 24, 2014, Siddhi Yoga ... 2014 in its Goa retreat . This is the ... winters, from November to March, Siddhi Yoga will organize four ... Goa. The Goa training sessions will conclude in March 2015. ... training, the 10th intake is also a 200 YTT ...
(Date:12/19/2014)... Wilmington, VT (PRWEB) December 19, 2014 ... full-service private ski club in Southern Vermont’s Deerfield Valley, ... trail names inspired by classic rock songs. , ... the weekend with a private concert followed by a ... said, “The new trail names include: “I’m Alright” the ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, ... ibuprofen, might slightly reduce your risk of developing a ... ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to reduce ... percent, the researchers concluded after reviewing nine prior studies. ... exposure. These painkillers "have potential as ...
(Date:12/17/2014)... 17, 2014 Dr. Myo Nwe is the ... Diet of the Future” and co-founder of the Ace Medical ... Dr. Nwe takes a broad look at the industry of ... under scientific scrutiny. On film and in television shows, however, ... toward the social aspects and played for basic laughs, which ...
Breaking Medicine News(10 mins):Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2
... ... heart function without need for cardiac stem cells , ... (Vocus) July 16, 2009 -- Injured heart tissue normally can,t regrow, ... heart tissue after a heart attack, in patients with heart failure, or in children with ...
... coronary function are restored , THURSDAY, JULY 23 (HealthDay ... tissue renew itself after a heart attack -- until now. ... to the heart become blocked, preventing enough oxygen from getting ... But researchers at Children,s Hospital Boston report progress toward someday ...
... , , PIPERSVILLE, Pa., July 23 ... the body,s mechanism for cooling itself is overactive and can cause ... than normal. While some people may only think about sweating during ... can disrupt their daily and recreational activities, regardless of the season. ...
... , ROANOKE, Va., July 23 Job ... The Virginia Psychological Association (VPA) and Virginia Academy of Clinical ... this cost by awarding the 2009 VPA/VACP Psychologically Healthy Workplace ... submit nominations. , , ...
... , , LOS ANGELES, July 23 ... AIDS Programs and Policy is launching its most comprehensive community outreach campaign ... of those who have HIV does not know it. , ... Titled "Virus," the multi-faceted campaign is designed to raise doubt ...
... , INDIANAPOLIS, July 23 Today, Eli ... the U.S. Food and Drug Administration (FDA) has approved a ... injection] to treat osteoporosis associated with sustained, systemic glucocorticoid therapy ... therapy is the most common cause of secondary osteoporosis, leading ...
Cached Medicine News:Health News:Study in this Week's Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 2Health News:Study in this Week's Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 3Health News:Injection May Heal Damaged Heart 2Health News:Photos: Don't Let Them See You Sweat This Summer 2Health News:Photos: Don't Let Them See You Sweat This Summer 3Health News:Photos: Don't Let Them See You Sweat This Summer 4Health News:Photos: Don't Let Them See You Sweat This Summer 5Health News:Los Angeles County Launches Its Most Comprehensive Campaign Ever to Encourage HIV Testing 2Health News:Los Angeles County Launches Its Most Comprehensive Campaign Ever to Encourage HIV Testing 3Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 2Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 3Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 4Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 5Health News:FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis 6
Comprifix Knee is a comfortable, lightweight, anatomically knitted knee support with an incorporated donut shaped insert for the reduction of pain and swelling....
... an adjustable extension/flexion stop with a ... increments. Adjust without tools. Simply rotate ... pins and reposition them as required.,Cushion ... with Velcro fasteners. All joints feature ...
... is the dynamic way to manage a ... proven effective in reducing contractures. Full ROM ... other therapies. Can also be used as ... stiffness and soft tissue contractures. Use where ...
... The Infrapatellar Band uses ... on the patellar tendon helping ... Schlatter and patella tendonitis. Focusing ... the tibial tubercle with less ...
Medicine Products: